ReviewOman journal of ophthalmology
The efficacy and safety of bleomycin injection as the primary management of orbital venolymphatic malformations: A systematic review.
Review in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Orbital venolymphatic malformation (OVLM) consists of abnormal vascular channels lined by endothelial cells with venous and lymphatic components. OVLM tends to re-grow after treatment, with a recurrence rate of 71.4% after surgery. The use of sclerotherapy injection has emerged as a nonsurgical procedure as extensive surgery may cause iatrogenic damage to vital structures within the orbit. Therefore, exploring the efficacy and safety profile of bleomycin injection for OVLM in achieving proptosis reduction, recurrence rate, visual acuity improvement or stabilization, and the complication of bleomycin is considered important. Current studies showed bleomycin resulted in proptosis reduction in 87.78% of patients and stayed stable in 12.22% of patients, with a median of 6 months' follow-up. The recurrence rate was 0.76% since only one patient had the recurrence due to rebleed and chocolate cyst formation. Visual acuity improved in 63.64% of patients, while 36.36% remained stable. Minimal complications were reported, including periocular hyperpigmentation (14.5%) and inflammation (8.40%). Bleomycin injection as a sclerotherapy is considered an effective and safe treatment modality for OVLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.